Products from BPS Bioscience require a minimum order value above 400€
Application: Useful as CD38-expressing target cells in co-culture assays with CD38 CAR-T cells, for both CD38-specific cell killing assay and cytokine production assay.
Background: CD38 (cyclic ADP-ribose hydrolase 1, ADPRC1) is a glycoprotein and ectoenzyme which plays an important role in regulating intracellular calcium. CD38 is a highly attractive target antigen for immunotherapy because it is highly expressed on multiple myeloma cells, and at relatively low levels on normal lymphoid and myeloid cells. Expression of CD38 has also been associated with HIV infection, leukemia, and type II diabetes mellitus. CD38 CAR-T is a T cell product engineered by retroviral transduction to express a fully human CD38-specific CAR (chimeric antigen receptor). In 2015, the FDA approved daratumumab (Darzalex), a breakthrough therapy drug targeting CD38, for the treatment of multiple myeloma.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866). Surface expression of CD20 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD20 expression (High, Medium) to mimic different stages of cancer target cells with various CD20 expression levels.
Host Cell Line: CHO
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Supplied As: Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Uniprot: P28907
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
References: 1. van de Donk, NW, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunological Reviews. 2016 Mar; 270: 95-1122. Drent, E, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered against T cells for the treatment of multiple myeloma. Haematologica. 2016 May; 101 (5): 616-6253. Sanchez, L, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. Journal of Hematology & Oncology. 2016 Jun; 9: 51
English
Deutsch
